Metastatic Breast Cancer Market Growth Drivers and Industry Services
According to Payal Rabde, who specializes in targeted therapies, HER2-targeted therapies, and precision oncology, biomarker-based diagnostics, with 4+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the metastatic breast cancer market. The global metastatic breast cancer market size was estimated at USD 22.8 billion in 2025 and is predicted to increase from USD 24.99 billion in 2026 to approximately USD 57.02 billion by 2035, expanding at a CAGR of 9.6% from 2026 to 2035. Her analysis highlights the increasing adoption of precision oncology therapies, antibody-drug conjugates, companion diagnostics, liquid biopsy, combination treatment, and AI-assisted oncology. The research also examines the competitive strategies of key industry participants, including, Roche Holding AG, AstraZeneca PLC, Eli Lilly Company, Merck & Co., Inc., MacroGenics Inc., Olema Pharmaceuticals and Mabwell Bioscience, shaping the future by expanding personalized oncology approaches, advancing next-generation targeted therapeutics, accelerating AI-driven drug discovery combinations, real-world evidence integration, and enhancing invasive disease monitoring in the global the metastatic breast cancer market.
Last Updated : 21 July 2026
Category: Life Sciences
Insight Code: 6858
Format: PDF / PPT / Excel